// App-Quantinova.ai

7036 : Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Hagop M. Kantarjian

  • Farhad Ravandi

  • Deborah A. Thomas

  • Jorge E. Cortes

  • Naveen Pemmaraju

  • Tapan M. Kadia

  • Nicholas James Short

  • Ghayas C. Issa

  • Rebecca S. Garris

  • Vicky Jeanis

  • H. Gal Moore

  • Guillermo Garcia-Manero

  • Gautam Borthakur

  • William G. Wierda

  • Evguenia Gachimova

  • Susan Mary O'Brien

  • Elias Jabbour

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, Irvine, Fullerton, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Acute lymphoblastic leukemia

  • Hypercarotenemia and vitamin A deficiency

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Vincristine

  • Prednisone

  • Ponatinib

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01424982

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved